Identifying and delineating the type 2 diabetes population in the Netherlands using an all-payer claims database: characteristics, healthcare utilisation and expenditures
- PMID: 34876422
- PMCID: PMC8655569
- DOI: 10.1136/bmjopen-2021-049487
Identifying and delineating the type 2 diabetes population in the Netherlands using an all-payer claims database: characteristics, healthcare utilisation and expenditures
Abstract
Objectives: We aimed to identify and delineate the Dutch type 2 diabetes population and the distribution of healthcare utilisation and expenditures across the health system from 2016 to 2018 using an all-payer claims database.
Design: Retrospective observational cohort study based on an all-payer claims database of the Dutch population.
Setting: The Netherlands.
Participants: The whole Dutch type 2 diabetes population (n=900 522 in 2018), determined based on bundled payment codes for integrated diabetes care and medication use indicating type 2 diabetes.
Outcome measures: Annual prevalence of type 2 diabetes, comorbidities and characteristics of the type 2 diabetes population, as well as the distribution of healthcare utilisation and expenditures were analysed descriptively.
Results: In 2018, 900 522 people (6.5% of adults) were identified as having type 2 diabetes. The most common comorbidity in the population was heart disease (12.1%). Additionally, 16.2% and 5.6% of patients received specialised care for microvascular and macrovascular diabetes-related complications, respectively. Most patients with type 2 diabetes received pharmaceutical care (99.1%), medical specialist care (97.0%) and general practitioner consultations (90.5%). In total, €8173 million, 9.4% of total healthcare expenditures, was reimbursed for the type 2 diabetes population. Medical specialist care accounted for the largest share of spending (38.1%), followed by district nursing (12.4%), and pharmaceutical care (11.5%).
Conclusions: All-payer claims databases can be used to delineate healthcare use: this insight can inform health policy and practice and, thereby, support better decisions to promote long-term sustainability of healthcare systems. The healthcare utilisation of the Dutch type 2 diabetes population is distributed across the health system and utilisation of medical specialist care is high. This is likely to be due to presence of concurrent morbidities and complications. Therefore, a shift from a disease-specific approach to a person-centred and integrated care approach could be beneficial in the treatment of type 2 diabetes.
Keywords: epidemiology; general diabetes; health economics.
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures
Similar articles
-
Evaluation of Healthcare Utilisation and Expenditures in Persons with Type 2 Diabetes Undergoing Bariatric-Metabolic Surgery.Obes Surg. 2024 Mar;34(3):723-732. doi: 10.1007/s11695-023-06849-z. Epub 2024 Jan 10. Obes Surg. 2024. PMID: 38198097 Free PMC article.
-
Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016-2018.Pharmacoecon Open. 2022 Mar;6(2):219-229. doi: 10.1007/s41669-021-00308-0. Epub 2021 Dec 4. Pharmacoecon Open. 2022. PMID: 34862962 Free PMC article.
-
Distribution of care expenditures for men and women with type 2 diabetes treated in primary care in the Netherlands: a case-control study (ZODIAC-59).BMJ Open. 2022 Feb 21;12(2):e052592. doi: 10.1136/bmjopen-2021-052592. BMJ Open. 2022. PMID: 35190426 Free PMC article.
-
Economic costs of diabetes in the U.S. In 2007.Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
Cited by
-
Disentangling Population Health Management Initiatives in Diabetes Care: A Scoping Review.Int J Integr Care. 2024 Jan 30;24(1):3. doi: 10.5334/ijic.7512. eCollection 2024 Jan-Mar. Int J Integr Care. 2024. PMID: 38312481 Free PMC article.
-
Real-World Research on Retinal Diseases Using Health Claims Database: A Narrative Review.Diagnostics (Basel). 2024 Jul 19;14(14):1568. doi: 10.3390/diagnostics14141568. Diagnostics (Basel). 2024. PMID: 39061705 Free PMC article. Review.
-
Linked survey and statutory health insurance data evaluating healthcare utilization patterns and associated factors of persons with diabetes in Germany - latent class analysis.Sci Rep. 2025 Apr 4;15(1):11646. doi: 10.1038/s41598-025-95514-9. Sci Rep. 2025. PMID: 40185820 Free PMC article.
-
Evaluation of Healthcare Utilisation and Expenditures in Persons with Type 2 Diabetes Undergoing Bariatric-Metabolic Surgery.Obes Surg. 2024 Mar;34(3):723-732. doi: 10.1007/s11695-023-06849-z. Epub 2024 Jan 10. Obes Surg. 2024. PMID: 38198097 Free PMC article.
-
Multi-Centre UK Analysis of Simultaneous Pancreas and Kidney (SPK) Transplant in Recipients With Type 2 Diabetes Mellitus.Transpl Int. 2024 Feb 2;36:11792. doi: 10.3389/ti.2023.11792. eCollection 2023. Transpl Int. 2024. PMID: 38370534 Free PMC article.
References
-
- Maarse H, Jeurissen P, Ruwaard D. Concerns over the financial sustainability of the Dutch healthcare system. DICE Rep 2013;11:32–6.
-
- WHO . Programmes and projects - Nutrition - Nutrition health topics - 5. Population nutrient intake goals for preventing diet-related chronic diseases. Available: https://www.who.int/nutrition/topics/5_population_nutrient/en/ [Accessed 13 Nov 2019].
-
- Williams R, Colagiuri S, Almutairi R. IDF diabetes atlas. 9th edn. Brussels, BE: International Diabetes Federation, 2019: 36–9.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical